Helus Pharma Completes Enrollment in Phase 3 HLP003 Trial
NEW YORK and TORONTO, July 21, 2026 Helus Pharma has announced the successful completion of patient enrollment ahead of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
NEW YORK and TORONTO, July 21, 2026 Helus Pharma has announced the successful completion of patient enrollment ahead of...
LOUISVILLE, Colo., July 21, 2026 Synergy Spine Solutions has announced a major commercial milestone for its FDA-approved Synergy Disc®,...
